In poor countries, where heart disease represents more than a quarter of the death toll, these cheap drugs are often unavailable. Spending just $200 million getting them to poor countries would avert 300,000 deaths each year. The lower burden on health systems, and the economic benefits, mean that an extra dollar spent on heart disease in a developing nation would achieve $25 worth of good.
When I started my research related (indirectly, yes, but still) to cardiovascular disease, I felt a little guilty because I thought it was a rich person's disease. That, of course, is false.